BIOTRONIK landed CE Mark approval for its Magmaris bioresorbable scaffold. This is the first “clinically proven” magnesium-based scaffold to come to market, offering advantages such as easier delivery and more strength resisting inward forces once deployed. The material is also resorbed faster by the body than polymer-based implants, and in pre-clinical tests the metal from the Magmaris was 95% gone within a year. Moreover, in a clinical trial the affected vessels exhibited healthy vasomotion often within six months of the implantation.
The edges of the device are electropolished to smooth out any irritating spots and the overall shape of the scaffold was designed to optimize coverage while optimizing resorption.
“CE mark approval for Magmaris opens a new horizon in the vascular therapeutic field,” said Dr. Daniel Buehler, President, Vascular Intervention at BIOTRONIK, in a statement. “We are eager to bring our magnesium scaffold to market, as we strongly believe that only a resorbable metal alloy can provide patients the distinctive advantages capable of addressing their future needs.”
Product page: Magmaris…
Source: BIOTRONIK…